The GeneAtlas System is designed to meet the life scientists demand for an easy to use and affordable way to interrogate the whole genome.
Affymetrix chief commercial officer Andy Last said they are excited to reach this agreement with Fisher Scientific because it allows us to expand our commercial sales in research markets while maintaining their focus further downstream in validation and clinical markets.
The strategic partnership will bring the superior microarray technology of Affymetrix to every lab, putting whole-genome analysis into the hands of every researcher who has been limited by budget and inhibited by the complexity of microarray systems.
Fisher Scientific president Dan Pantano said they are also excited to be entering into this relationship with Affymetrix; it broadens their extensive genomic research portfolio and allows them to offer a full suite of solutions from discovery research through to validation.
"By partnering with the industry innovator and pioneer in microarray technology it provides Fisher Scientific an opportunity to offer customers a premium option when faced with challenging genomic research, and the GeneAtlas System is the perfect solution for many customers we routinely serve," Pantano said.
